Name : Human CD79B Protein
Product Source :
Recombinant Human CD79B Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala29-Asp159.[Accession | P40259-1]
Molecular Weight :
The protein has a predicted MW of 18.1 kDa. Due to glycosylation, the protein migrates to 33-42 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CD79B on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Human CD79B, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-CD79B Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.
Background :
CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
Synonyms :
B29; CD79b molecule; CD79B; IGB; IGBAGM6; Ig-beta; Ig-β
References & Citations :
(1)Dornan D , Bennett F , Chen Y , et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 114(13):2721-2729.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Nucleoprotein/NP ProteinBiological Activity
Intrinsic Factor/GIF Proteincustom synthesis
Popular categories:
Serpin B11
E-Cadherin/Cadherin-1